Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes (Q33414468)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

4

object named as

Jane N Winter

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeanne M. Horowitz

object named as

Jeanne M Horowitz

5

0 references

Martin S. Tallman

10

object named as

Martin S Tallman

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Olga Frankfurt

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shuo Ma

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leo Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alfred Rademaker

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bing Bing Weitner

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

LoAnn C Peterson

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jessica K Altman

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adam Petrich

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Steven T Rosen

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

17 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

315-323

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Rapid infusion of rituximab over 60 min.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Autoimmune complications of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Richter's transformation in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Risk of second cancer after chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Subsequent Neoplasia in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.910654

21 January 2018

Identifiers

10.3109/10428194.2014.910654

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33414468&oldid=1536327894"